Mark Shalauta, MD
Family Medicine · San Diego, CANPI 1902864358
Payments from drug & device makers
Across 27 payments — averaging $80.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi Pasteur Inc.$740
- GSK$443
- Pfizer$158
- Merck$156
- Alnylam Pharmaceuticals Inc.$146
- Amgen$130
- plus $397 from 5 others
What the payments were for
- Consulting fees$49423%
- Food & beverage$1,67577%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi Pasteur Inc. | 3 | $740 |
| GSK | 11 | $443 |
| Pfizer | 3 | $158 |
| Merck | 3 | $156 |
| Alnylam Pharmaceuticals Inc. | 1 | $146 |
| Amgen | 1 | $130 |
| Bayer | 1 | $104 |
| E.r. Squibb & Sons, L.L.C. | 1 | $97 |
| Dynavax Technologies Corporation | 1 | $94 |
| Exact Sciences | 1 | $76 |
| Novo Nordisk | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLUZONE HIGH-DOSE$494
- NO PRODUCT DISCUSSED$146
- AMVUTTRA$146
- Repatha$130
- SHINGRIX$122
- BEXSERO$122
- PNEUMOVAX 23$118
- VYNDAQEL$116
- Kerendia$104
How this compares
$2,169 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 68 | $1,073 |
| Atorvastatin Calcium | 140 | $1,036 |
| Pravastatin Sodium | 76 | $673 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 46 | $635 |
| Losartan Potassium | 70 | $596 |
| Rosuvastatin Calcium | 25 | $522 |
| Fluticasone Propionate | 18 | $508 |
| Duloxetine Hcl | 15 | $462 |
| Metoprolol Succinate | 24 | $441 |
| Pantoprazole Sodium | 27 | $419 |
| Tamsulosin Hcl | 37 | $411 |
| SynthroidLevothyroxine Sodium | 14 | $400 |
| Telmisartan | 12 | $370 |
| Escitalopram Oxalate | 21 | $351 |
| Gabapentin | 15 | $342 |
Paid to pharmacies, not to this prescriber.
Other family medicine in San Diego
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Laurie Han-ConradSan Diego$2.9M
- Sheldon MorrisSan Diego$1.1M
- Mirwais SaifiSan Diego$1M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.